Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010322 · ClinicalTrials.gov registry record · Phase 3
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00010322 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics.
The verdict
NCT00010322, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or without atamestane. PURPOSE: Randomized phase III trial to compare the effectiveness of toremifene with or without atamestane in treating postmenopausal women who have metastatic breast cancer.
Interventions
- DRUG atamestane
- DRUG toremifene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010322
The ClinicalTrials.gov registry entry for NCT00010322 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which atamestane is the first listed.
NCT00010322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010322 about?
NCT00010322 is a clinical study titled "Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or withou...
What is the current status of trial NCT00010322?
This trial is currently terminated. It is a Phase 3 study. The study started on 2000-10. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00010322?
The interventions under investigation include: atamestane (DRUG), toremifene (DRUG).
Who is sponsoring clinical trial NCT00010322?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.